Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Neuron23 names Kathy Dong to its board

By Brian Buntz | June 15, 2022

Neuron23The early-stage biotechnology firm Neuron23 has recruited the chief operating officer of Star Therapeutics, Kathy Dong, to join its board of directors.

Founded in 2018, Neuron23 (South San Francisco) specializes in the discovery and development of drugs for neurodegenerative and immunological diseases, drawing insights from data science.

Star Therapeutics (South San Francisco) focuses on the discovery and development of therapeutics that can treat multiple rare diseases.

Before joining Star Therapeutics, Dong worked for a number of pharma companies, including Gilead Sciences, True North Therapeutics and Sanofi.

Kathy Dong

Kathy Dong

At Gilead, she oversaw the commercial launch of hepatitis B and C therapies such as SOVALDI (sofosbuvir) and HARVONI (ledipasvir/sofosbuvir).

“I am thrilled to welcome someone of Kathy’s caliber and expertise to Neuron23’s board of directors,” said Nancy Stagliano, CEO of Neuron23, in a press release. “For the past 15 years, Kathy has progressed programs into the clinic and to market, many of which have led to significant scientific and medical advances. As a board member, her guidance will help ensure we continue to progress our pipeline to the clinic and ultimately to patients who are in need of new treatment options for neurological and immunological diseases.”

“As Neuron23 prepares to advance NEU-723 into clinical trials for Parkinson’s disease and continues to make progress in additional programs, I am excited to work with Dr. Stagliano, our board, and our brilliant team of scientists to bring personalized therapies to patients with limited treatment options,” Dong said in a press release.

Dong received Pharm.D. and MBA degrees from the University of New Mexico and completed a postdoctoral fellowship at Rutgers University.

Earlier this year, Neuron23 closed a $100 million Series C financing round.


Filed Under: Neurological Disease
Tagged With: Kathy Dong, Neuron23, Star Therapeutics
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Astellas Pharma in the Drug Discovery & Development Pharma 50
FDA places clinical hold on Astellas clinical trial focused on Pompe disease
FDA
FDA launches 5-year initiative for rare neurodegenerative diseases 
Biogen in the Drug Discovery & Development Pharma 50
Biogen halts observational post-marketing study of aducanumab
Amylyx
Inside Canada’s approval of Amylyx’s ALS drug Albrioza

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50